Analyzes FDA FAERS adverse event reports for semaglutide (all formulations: Ozempic, Wegovy, Rybelsus). Provides comprehensive post-market safety surveillance including most reported adverse events by frequency, patient demographics, severity classifications, and specific tracking of key safety concerns (muscle mass loss, gallbladder issues, pancreatitis).